7.03
price up icon3.53%   0.24
after-market 시간 외 거래: 6.99 -0.04 -0.57%
loading
전일 마감가:
$6.79
열려 있는:
$6.76
하루 거래량:
1.67M
Relative Volume:
0.78
시가총액:
$499.63M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-4.3129
EPS:
-1.63
순현금흐름:
$-71.49M
1주 성능:
-4.48%
1개월 성능:
+12.84%
6개월 성능:
-3.70%
1년 성능:
+156.57%
1일 변동 폭
Value
$6.64
$7.03
1주일 범위
Value
$6.45
$7.31
52주 변동 폭
Value
$2.315
$14.84

알티뮨 Stock (ALT) Company Profile

Name
명칭
Altimmune Inc
Name
전화
(240) 654-1450
Name
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
직원
59
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
ALT's Discussions on Twitter

알티뮨 Stock (ALT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-04-29 다운그레이드 Guggenheim Buy → Neutral
2024-01-24 개시 Goldman Neutral
2023-03-22 다운그레이드 Goldman Buy → Neutral
2022-12-01 개시 Goldman Buy
2021-12-29 재개 Jefferies Buy
2021-06-02 개시 H.C. Wainwright Buy
2021-02-11 개시 Guggenheim Buy
2020-12-14 개시 Jefferies Buy
2020-11-12 재확인 B. Riley Securities Buy
2020-09-25 개시 B. Riley FBR Buy
2020-08-14 개시 Evercore ISI Outperform
2020-07-31 개시 Piper Sandler Overweight
2020-07-28 개시 JMP Securities Mkt Outperform
2020-02-24 재개 ROTH Capital Buy
2019-07-19 개시 ROTH Capital Buy
2017-10-09 개시 Piper Jaffray Overweight
모두보기

알티뮨 주식(ALT)의 최신 뉴스

pulisher
04:17 AM

Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat

04:17 AM
pulisher
Nov 04, 2024

Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan

Nov 04, 2024
pulisher
Oct 30, 2024

Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide - RTTNews

Oct 30, 2024
pulisher
Oct 29, 2024

Altimmune (NASDAQ:ALT) Trading Up 7%Here's What Happened - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Altimmune (ALT) Price Target Increased by 9.39% to 19.53 - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 26, 2024

When (ALT) Moves Investors should Listen - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 25, 2024

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: C - GuruFocus.com

Oct 25, 2024
pulisher
Oct 25, 2024

Altimmune Jumps 66% After Positive Results for Its Obesity Drug - MSN

Oct 25, 2024
pulisher
Oct 24, 2024

Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Oct 23, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Altimmune Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Altimmune, Inc. (ALT): A Bull Case Theory - MSN

Oct 17, 2024
pulisher
Oct 17, 2024

Exchange Traded Concepts LLC Has $1.33 Million Position in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Millennium Management LLC Increases Stake in Altimmune Inc - Yahoo Finance

Oct 16, 2024
pulisher
Oct 15, 2024

Altimmune (NASDAQ:ALT) Trading Up 10.7%Should You Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Learn to Evaluate (ALT) using the Charts - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 10, 2024

Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada

Oct 09, 2024
pulisher
Oct 04, 2024

Where are the Opportunities in (ALT) - Stock Traders Daily

Oct 04, 2024
pulisher
Oct 02, 2024

Consider Buying Potential Takeover Target Altimmune (NASDAQ:ALT) - Seeking Alpha

Oct 02, 2024
pulisher
Oct 01, 2024

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - The Manila Times

Oct 01, 2024
pulisher
Sep 30, 2024

Altimmune completes enrollment for MASH treatment trial By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Altimmune completes enrollment for MASH treatment trial - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis - Marketscreener.com

Sep 30, 2024
pulisher
Sep 29, 2024

Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Sep 29, 2024
pulisher
Sep 28, 2024

Profund Advisors LLC Sells 94,081 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Altimmune stock rides wave of promising obesity drug data - Investing.com

Sep 27, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Altimmune Inc [ALT] Investment Guide: What You Need to Know - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Has $184,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

SEC Form FWP filed by Alta Global Group Limited - Quantisnow

Sep 24, 2024
pulisher
Sep 24, 2024

How the (ALT) price action is used to our Advantage - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Unique Fabricating (NYSEAMERICAN:UFAB) Trading Down 17.6% - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

StockWatch: FDA Surprise Lifts Expectations for Applied’s Govorestat - Genetic Engineering & Biotechnology News

Sep 23, 2024
pulisher
Sep 21, 2024

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects (NASDAQ:ALT) - Seeking Alpha

Sep 21, 2024
pulisher
Sep 20, 2024

Altimmune (NASDAQ:ALT) Trading Up 3.7% - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Milan Fashion Week: At Gucci, making fashion wearable - CNA Luxury

Sep 20, 2024
pulisher
Sep 20, 2024

The Best Celebrity Shoes at Gucci’s Spring 2025 Show in Milan: Kirsten Dunst, Lucky Blue Smith, Nara Smith and More - Footwear News

Sep 20, 2024
pulisher
Sep 20, 2024

"Commit To It and Do It": Mel and Lyas Gather the Girls for a Gucci SS25 Debrief - Interview

Sep 20, 2024
pulisher
Sep 20, 2024

Take a look at celebrities' outfits for Milan Fashion Week's Gucci show - Marca English

Sep 20, 2024
pulisher
Sep 20, 2024

Sabato swings into the sixties: What went down at Gucci SS25 - Dazed

Sep 20, 2024
pulisher
Sep 20, 2024

TikTok Star Nara Smith Stuns at Gucci’s Spring 2025 Show in Patent Leather Signoria Slingback Pumps at Milan Fashion Week - Yahoo Entertainment

Sep 20, 2024
pulisher
Sep 19, 2024

Applied Therapeutics stock surges after FDA update - The Pharma Letter

Sep 19, 2024
pulisher
Sep 19, 2024

Altimmune (NASDAQ:ALT) Trading Down 4.5% - MarketBeat

Sep 19, 2024
pulisher
Sep 17, 2024

Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club - The Motley Fool

Sep 17, 2024

알티뮨 (ALT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):